Investing.com - Avadel Pharma reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Avadel Pharma announced earnings per share of $-0.19 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.2557 on revenue of $0.00.
Avadel Pharma shares are up 10% from the beginning of the year, still down 43.07% from its 52 week high of $13.49 set on April 27, 2020. They are outperforming the Euro Stoxx 50 which is up 6.48% from the start of the year.
Avadel Pharma shares gained 1.99% in intra-day trade following the report.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by Medtronic on February 23, who reported EPS of $1.29 on revenue of $7.78B, compared to forecasts EPS of $1.15 on revenue of $7.77B.
AstraZeneca ADR had missed expectations on February 11 with fourth quarter EPS of $0.535 on revenue of $7.41B, compared to forecast for EPS of $0.5504 on revenue of $7.12B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar